Acumen Pharmaceuticals (Acumen Pharmaceuticals) 1-Year ROIIC % : -31.94% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acumen Pharmaceuticals 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Acumen Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Dec. 2023 was -31.94%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Acumen Pharmaceuticals's 1-Year ROIIC % or its related term are showing as below:

ABOS's 1-Year ROIIC % is ranked worse than
59.85% of 1462 companies
in the Biotechnology industry
Industry Median: -2.96 vs ABOS: -31.94

Acumen Pharmaceuticals 1-Year ROIIC % Historical Data

The historical data trend for Acumen Pharmaceuticals's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acumen Pharmaceuticals 1-Year ROIIC % Chart

Acumen Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

1-Year ROIIC %

-2.26

-42.49

177.25

-31.94

Acumen Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
1-Year ROIIC %	Get a 7-Day Free Trial												177.25	-143.40	-270.96	-25.89	-31.94

Competitive Comparison of Acumen Pharmaceuticals's 1-Year ROIIC %

For the Biotechnology subindustry, Acumen Pharmaceuticals's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's 1-Year ROIIC % falls into.

Acumen Pharmaceuticals 1-Year ROIIC % Calculation

Acumen Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

1-Year ROIIC %	=	1-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	1-Year Incremental Invested Capital
	=	( -61.138 (Dec. 2023) - -45.237 (Dec. 2022) )	/	( 68.28 (Dec. 2023) - 18.502 (Dec. 2022) )
	=	-15.901	/	49.778
	=	-31.94%^***

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Acumen Pharmaceuticals (NAS:ABOS) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Acumen Pharmaceuticals 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Acumen Pharmaceuticals's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acumen Pharmaceuticals (Acumen Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acumen Pharmaceuticals Inc (NAS:ABOS) » Definitions » 1-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

427 Park Street, Charlottesville, VA, USA, 22902

Website

https://www.acumenpharm.com

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Executives

Daniel Joseph Oconnell	director, officer: President and CEO	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Derek M Meisner	officer: Chief Legal Office & Corp Sec	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Eric Siemers	officer: Chief Medical Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Russell Barton	officer: Chief Operating Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Matt Zuga	officer: Chief Financial Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Nathan B Fountain	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Sands Capital Global Venture Fund Ii, L.p.	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209
Sands Capital Life Sciences Pulse Fund, Llc	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209